References

1. J Chronic Dis 1959;10:218-248

2. Bull History Med 1982;56:1-18

3. Code of Federal Regulations 21.201.56. Drugs. Labeling. General requirements on content and format of labeling for human prescription drugs

4. FDA Guidance documents for regulated industry. Available at www.fda.gov/opacom/morechoices/industry/guidedc.htm

5. ICH guidance documents. Available at www.ich.org/cache/ compo/276-254-1.html

6. International Conference on Harmonization. Guidance on general considerations for clinical trials. Federal Register 62(242). Feb. 17, 1997

7. Code of Federal Regulations 21.312.53 IND. General responsibilities of sponsors. Selecting investigators and monitors.

8. Code of Federal Regulations 21.312.56. IND. General responsibilities of sponsors. Review of ongoing investigations.

9. Code of Federal Regulations 21.312.32 IND. Safety reports. 10. Code of Federal Regulations 21.310.305 Records and reports concerning adverse drug experiences on marketed prescription drugs for human use without approved new drug applications (CFR, Adverse Events)

11. Levine R. Getting past the IRB roadblock. Pharmaceutical Executive 2003;23(12):76-82

12. Anonymous. Working with institutional review boards and informed consent. DIA Forum 2002;(7):16-20

13. Successful clinical trials management. An imposing change (EDC). Pharmaceutical Executive Supplement, June 2004

14. King J. Electronic submissions. Is anybody ready? R&D Directions 2003;9(10):34-40

15. Anonymous. Introduction to audit programs. DIA Forum 2003;(1):24-27

16. Successful clinical trials management. Wanted clinical investigators. Pharmaceutical Executive Supplement, June 2004

17. King J. 10 ways to faster and easier patient recruitment. R&D Directions 2004;10(4):34-46

18. US Code of Federal Regulations CFR21 Part 50. Protection of human subjects

19. ICH E6 Good Clinical Practice: Consolidated Guideline (patient consent)

20. Schneider BA. Independent data and safety monitoring. DIA Today 2005;5(3):34-35

21. PR News Wire via Dow Jones, December 17, 2005

22. ICH E3 guideline. Structure and content of clinical study reports

23. Anonymous. Tufts Center for Study of Drug Development Outlook 2002 Boston. MA

24. Sentek K, Engel S. Special report on contract research organizations. The turnaround. R&D Directions 2002;8(8):44-94

25. Anonymous. Successful clinical trials management. Working with CROs. Pharmaceutical Executive Supplement, June 2004

26. King J, Jackson A. Adjustments along the way (CROs). R&D Directions 2003;9(8):38-55

27. Lamberti MJ (ed). An Industry in Evolution, 4th ed. Thomson CenterWatch, Boston, MA, 2004, p. 61

28. Lamberti MJ (ed). An Industry in Evolution, 4th ed. Thomson CenterWatch, Boston, MA, 2004, p. 72

29. Lamberti MJ (ed). An Industry in Evolution, 4th ed. Thomson CenterWatch, Boston, MA, 2004, p. 76

30. Lamberti MJ (ed). State of the Clinical Trials Industry. Thomson CenterWatch, Boston, MA, 2005, p. 177

31. (pg 79) (cancer audit of patients in trials)

32. FDA. Guidance for Industry: Information Program on Clinical Trials for Serious or Life-Threatening Diseases or Conditions. Available at http://fda.gov/cder/guidance/index.htm

33. Clinical Trial Registration: a statement from the International Committee of Medical Journal Editors. Lancet 2004;364(9438): xx-xx

34. positive controls and approval creep

35. J Clin Oncology 2003;21(7):1404-1411.

36. Bernard S. The 5 myths of pharmacogenomics. Pharmaceutical Executive 2003;23(10):70-78

Was this article helpful?

0 0
Outsourcing Survival Kit

Outsourcing Survival Kit

Tired Of Being Tied Down By Time? Wish You Could Achieve More And Earn More Within The Deadlines You Are Given? Want To Branch Out To Other Lucrative Areas Without Sacrificing Your Current Business?

Get My Free Ebook


Post a comment